Enrolling by invitationNot a drug-phase studyRelapsing MSNCT06641271

What it found

Still running

No result yet.

What was tested

Treatment tested

  • Closed Loop Trans-Auricular Vagus Nerve Stimulation System

Placebo or sham

  • Placebo

What it measured

Main measures

  • Frequency of adverse events in response to paired-taVNS treatment

    End of Study (6 months)

    Safety

Other measures (9)

  • Change from baseline in time to complete the grooved peg test

    End of Study (6 months)

  • Change from baseline of score of the upper extremity portion of the Fugl-Meyer Assessment

    End of Study (6 months)

    Arm and hand function
  • Change from baseline score of the Expanded Disability Status Scale

    End of Study (6 months)

    Disability progression
  • Change in time from baseline to complete the timed 25 foot walk test

    End of Study (6 months)

    Disability progressionWalking and mobility
  • Change from baseline in composite disability metric

    End of Study (6 months)

    Disability progressionWalking and mobility
  • Change in Dellon-Modified Moberg Pick-Up Test

    End of Study (6 months)

  • Change from baseline in patient reported outcomes from the multiple sclerosis impact scale 29

    End of Study (6 months)

    Quality of life (reported by participants)
  • Motor Evoked Potential

    End of Study (6 months)

    Myelin repairNerve conduction tests
  • Visual Evoked Potential

    End of Study (6 months)

    Myelin repair

Who could take part

Relapsing MS · 18 to 70

Inclusion Criteria: * All participants ages 18-70 with diagnosis of multiple sclerosis at least 30 days from last relapse * Baseline grooved peg test time greater than or equal to 91 seconds for completion of the task (2 standard deviation above mean multiple sclerosis score). * Ability to sign informed consent * Expanded disability status scale score (or estimated) of 2.5 or greater OR a clinical report of upper extremity dysfunction in their dominant hand Exclusion Criteria: * Current uncontrolled and/or clinically significant medical condition. * History of seizures or epilepsy. * Other central nervous system disease or significant brain trauma. * Bacterial or viral infection within the prior 30 days. * Prior treatment with total body irradiation, clemastine, bexarotene, or other experimental remyelinating agent. * Recent suicide attempt or continued expressed suicidal ideation. * Implanted devices, such as pacemakers, cochlear prosthesis, neuro-stimulators. * Abnormal ear anatomy or ear infection. * Pregnancy, lactation, or lack of use of contraception. * Unable to walk 25 feet continuously * Other significant disease or disorder that might impair study participation. Participants will be allowed to initiate or maintain background disease modifying therapy to reduce the risk of multiple sclerosis relapse and optimize recruitment.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function. The main questions it aims to answer are: * Is stimulating the vagus nerve safe and feasible after demyelinating episodes? * Does a paired motor task with vagus nerve stimulation improve motor function with someone who has multiple sclerosis? Researchers will compare active vagus nerve stimulation to a sham stimulation to see if the paired vagus nerve stimulation can improve motor control. Participants will: * Come in for study visits over a six month period. Study visits are three times weekly for the first month, then single follow up visits at two, three, and six months. * During study visits, participants will complete 30 minutes of the paired vagus nerve stimulation with a motor task, specifically the grooved peg test. * At various timepoints throughout the study, motor, disability, and neurophysiological assessments will be administered, including the Timed 25-Foot Walk Test, Expanded Disability Status Scale (EDSS), Upper Extremity portion of the Fugl-Meyer Assessment, Dellon-Modified Moberg Pick-Up Test, Multiple Sclerosis Impact Scale-29 (MSIS-29), motor evoked potentials (MEPs), and visual evoked potentials (VEPs). MRI assessments will also be performed to evaluate exploratory imaging metrics of potential remyelinative efficacy.

Papers

    Loading reviews and guidelines…

    History

      1. Started

        Jan 2025

      2. Main results due

        Jul 2031

      3. Finished

        Jul 2031

      Assembled by software from public sources and not checked by people. Each record links to its source. Report an error